Table 1.
Demographics of the study population
| Variables | Aspirin + clopidogrel group (n = 46) |
Aspirin + ticagrelor group (n = 66) |
P |
|---|---|---|---|
| Age, yrs. | 58.1 ± 9.1 | 56.3 ± 11.6 | 0.401 |
| Male, n (%) | 36(78.3) | 55(83.3) | 0.499 |
| BMI, kg/m2 | 25.9 ± 3.3 | 25.9 ± 3.2 | 0.963 |
| LVEF, % | 63.0(60.0, 66.0) | 60.0(52.8, 65.0) | < 0.001 |
| Risk factors | |||
| Hypertension, n (%) | 33(71.7) | 31(47.0) | 0.009 |
| Diabetes, n (%) | 9(19.6) | 26(39.4) | 0.026 |
| Hyperlipidemia, n (%) | 43(93.5) | 58(89.2) | 0.441 |
| Past history | |||
| Previous PCI, n (%) | 9(19.6) | 28(42.4) | 0.011 |
| Previous MI, n (%) | 17(37.0) | 56(84.8) | < 0.001 |
| Previous stroke, n (%) | 10(22.2) | 4(6.1) | 0.012 |
| Medications | |||
| Statins, n (%) | 46(100.0) | 66(100.0) | 1.000 |
| ACEI, n (%) | 11(24.4) | 29(46.0) | 0.022 |
| ARB, n (%) | 8(18.2) | 7(11.1) | 0.300 |
| β-blocker, n (%) | 38(84.4) | 60(93.8) | 0.112 |
| Laboratory | |||
| Hemoglobin, g/L | 147.7 ± 14.0 | 143.5 ± 12.4 | 0.095 |
| LDL-C, mmol/L | 2.0(1.7, 2.8) | 2.2(1.5, 2.7) | 0.708 |
| HsCRP, mg/L | 1.1(0.5, 3.0) | 2.6(1.2, 7.2) | 0.006 |
| AST, U/L | 22.0(19.0, 27.5) | 27.0(20.0, 85.0) | 0.007 |
| ALT, U/L | 27.0(17.0, 39.2) | 32.5(22.8, 52.5) | 0.022 |
| Platelet, 109 cells/L | 223.1 ± 60.2 | 244.7 ± 69.7 | 0.091 |
| MPV, fL | 11.4 ± 1.4 | 10.2 ± 0.9 | < 0.001 |
Values are mean ± SD if the distribution is normal; median (interquartile range) if skewed; number, n (proportions, %) for categorical variables
ACEI Angiotensin converting enzyme inhibitor, ALT Alanine transaminase, AST Aspartate transaminase, ARB Angiotensin receptor blocker, BMI Body mass index, CABG Coronary artery bypass graft, hsCRP highly sensitive C-reactive protein, LDL-C Low-density lipoprotein cholesterol, LVEF Left ventricular ejection fraction, MI Myocardial infarction, MPV Mean platelet volume, PCI Percutaneous coronary intervention